通心络胶囊对不稳定型心绞痛患者血浆内皮素和降钙基因相关肽的影响

目的 :探讨通心络胶囊对不稳定型心绞痛 (UAP)患者的治疗作用。方法 :对 90例UAP患者用通心络胶囊 (6 0例 )及复方丹参片 (30例 )治疗 ,观察治疗前后血浆内皮素 (ET)、降钙基因相关肽(CGRP)含量 ,并与 2 0名健康人作比较。结果 :UAP患者血浆ET明显高于健康人 (P <0 0 5 ) ,CGRP明显低于健康人 (P <0 0 5 )。通心络胶囊治疗后患者ET明显下降 (P <0 0 1) ,CGRP明显升高 (P <0 0 5 ) ;复方丹参片治疗后ET明显下降 (P <0 0 5 ) ,CGRP无明显改变 (P >0 0 5 ) ;通心络组降低ET、升高CGRP作用明显优于复方丹参片组 (均P <0 0 5 )。结论 :通心络胶囊能有效调节ET、CGRP代谢失衡状况 ,减少心肌缺血损伤程度 ,是治疗UAP的有效药物

英文摘要:

Objective: To investigate the effect of Tongxinluo capsule (TXLC) on the patients with unstable angina pectoris (UAP). Methods: Patients of UAP were divided into two groups, the treated group (n=60) was treated with TXLC and the Danshen group (n=30) was treated with composite Danshen tablet. The plasma endothelin (ET) and calcitonin gene related peptide (CGRP) were measured before and after treatment. Data were compared between the two groups and also compared with those measured in 20 healthy subjects for control. Results: ET level was higher and CGRP level lower significantly in UAP patients than that in healthy subjects significantly (P<0 05). After TXLC treatment, ET significantly lowered (P<0 01) and CGRP increased (P<0 05). But in the Danshen group after treatment, the former decreased (P<0 05), while the latter remained unchanged (P>0 05). The effect of TXLC was better than that of composite Danshen tablet. Conclusion: TXLC is an effective drug for UAP treatment, which could efficiently regulate the ET and CGRP metabolism and ameliorate the degree of myocardial ischemia damage.

关闭